An exciting new study led by the Institut de Neurociències at the Autonomous University of Barcelona (INc-UAB) has revealed promising results in promoting healthy aging and longevity. The research focuses on the role of the Klotho protein in mice and its impact on physical and cognitive health as they age.
As individuals grow older, they naturally experience a decline in muscle and bone mass, making them more vulnerable to frailty and injuries. Additionally, cognitive functions deteriorate, leading to neurodegenerative conditions like Alzheimer’s and Parkinson’s. With the global population aging rapidly, finding ways to mitigate these effects has become a critical area of research.
The study, recently published in Molecular Therapy, involved treating young mice with gene therapy vectors to increase the secretion of the secreted form of the Klotho protein (s-KL). Remarkably, at 24 months of age, equivalent to 70 human years, the treated mice displayed improved muscle, bone, and cognitive health.
Professor Miguel Chillón, the lead researcher, explained, “We have been exploring the therapeutic potential of the Klotho protein for neurodegenerative diseases. In this study, we aimed to investigate its impact on healthy aging by examining a wide range of factors.”
The results were impressive, with mice treated with s-KL living 15-20% longer and exhibiting enhanced physical performance, larger muscle fibers, and reduced fibrosis, indicating improved muscle health. Moreover, female mice showed better bone health, with greater preservation of internal bone structures, suggesting a protective effect against osteoporosis.
In the brain, s-KL treatment led to the generation of new neurons and increased immune activity in the hippocampus, hinting at potential cognitive benefits. The viral vector therapy involved introducing the gene for s-KL into the mice’s cells, enabling them to produce the protein independently. The vectors were administered intravenously and directly into the brain to ensure brain cells also produced s-KL.
Joan Roig-Soriano, the first author of the study, highlighted the potential of this therapy for humans, saying, “We now have viral vectors that can reach the brain after being administered intravenously, which could facilitate the safe translation of this therapy to humans.”
The research team has already patented the use of Klotho for cognitive deficits and filed three new patents following this study. These patents protect the use of Klotho for treating bone and muscle deficits and developing therapies to enhance longevity.
In conclusion, the researchers believe that if an effective delivery method for s-KL is found, it could significantly improve people’s quality of life and contribute to building a healthier society. This groundbreaking study paves the way for potential advancements in promoting healthy aging and longevity.
For more information, the study titled “Long-term effects of s-KL treatment in wild-type mice: Enhancing longevity, physical well-being, and neurological resilience” can be found in Molecular Therapy.
